Whereas reactivated CD8+CD20+ T cells at the CNS borders are expected to enter the CNS parenchyma and participate in nervous tissue damage in patients with MS, we questioned what function border-patrolling CD4+CD20+ T cells were committed to upon activation. This evidence concerns the gene CD8A and myeloid sarcoma.